<DOC>
	<DOCNO>NCT02309359</DOCNO>
	<brief_summary>The purpose study assess efficacy safety dose regimens ALX-0061 administer subcutaneously ( s.c. ) combination methotrexate ( MTX ) subject active RA despite MTX therapy , compare placebo . To assess effect ALX-0061 quality life , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , immunogenicity ALX-0061 , define optimal dose regimen ALX-0061 , base safety efficacy , clinical development .</brief_summary>
	<brief_title>A Dose-Range Finding Study ALX-0061 Combination Therapy Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis RA least 6 month prior screen , ACR functional class IIII Subjects treat tolerate MTX Active RA Others define protocol Have treat DMARDs/systemic immunosuppressive MTX . Have receive approved investigational biological target synthetic DMARD therapy RA le 6 month prior screen . Have history toxicity , nontolerance , primary nonresponse inadequate response biological therapy , target synthetic DMARDs , RA . Have receive prior therapy block interleukin6 ( IL6 ) pathway , time . Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>